<SEC-DOCUMENT>0001144204-18-064734.txt : 20181217
<SEC-HEADER>0001144204-18-064734.hdr.sgml : 20181217
<ACCEPTANCE-DATETIME>20181214215148
ACCESSION NUMBER:		0001144204-18-064734
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20181213
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20181217
DATE AS OF CHANGE:		20181214

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			APPLIED DNA SCIENCES INC
		CENTRAL INDEX KEY:			0000744452
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-MISCELLANEOUS BUSINESS SERVICES [7380]
		IRS NUMBER:				592262718
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0930

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36745
		FILM NUMBER:		181236862

	BUSINESS ADDRESS:	
		STREET 1:		50 HEALTH SCIENCES DRIVE
		CITY:			STONY BROOK
		STATE:			NY
		ZIP:			11790
		BUSINESS PHONE:		631-240-8800

	MAIL ADDRESS:	
		STREET 1:		50 HEALTH SCIENCES DRIVE
		CITY:			STONY BROOK
		STATE:			NY
		ZIP:			11790

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PROHEALTH MEDICAL TECHNOLOGIES INC
		DATE OF NAME CHANGE:	20010504

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	DCC ACQUISITION CORP
		DATE OF NAME CHANGE:	19990211

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	DATALINK CAPITAL CORP/TX/
		DATE OF NAME CHANGE:	19980306
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>tv509245_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 12pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>WASHINGTON, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM 8-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CURRENT REPORT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PURSUANT TO SECTION 13 OR 15(d) OF THE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES EXCHANGE ACT OF 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Date of Report (Date of earliest event reported):
December 17, 2018 (December 13, 2018)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 14pt"><B>Applied
DNA Sciences, Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact name of registrant as specified in
its charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 33%; padding-right: 3pt; padding-left: 3pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.8pt 0pt 0; text-align: center"><B>Delaware</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.8pt 0pt 0; text-align: center">(State or other jurisdiction<BR>
        of incorporation)</P></TD>
    <TD STYLE="width: 34%; padding-right: 3pt; padding-left: 3pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.8pt 0pt 0; text-align: center"><B>001-36745</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.8pt 0pt 0; text-align: center">(Commission File Number)</P></TD>
    <TD STYLE="width: 33%; padding-right: 3pt; padding-left: 3pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.8pt 0pt 0; text-align: center"><B>59-2262718</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.8pt 0pt 0; text-align: center">(IRS Employer</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.8pt 0pt 0; text-align: center">Identification No.)</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>50 Health Sciences Drive</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Stony Brook, New York 11790</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Address of principal executive offices;
zip code)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Registrant&rsquo;s telephone number, including
area code:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>631-240-8800</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>N/A</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Former name or former address, if changed
since last report)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 1%; padding: 0; text-align: justify; text-indent: 0">&nbsp;</TD>
    <TD STYLE="width: 4%; padding: 0; text-indent: 0"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD>
    <TD STYLE="width: 95%; padding: 0; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD>
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD>
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD>
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&sect;230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&sect;240.12b-2 of this chapter). Emerging growth company
</FONT><FONT STYLE="font-family: Wingdings">&uml;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </FONT><FONT STYLE="font-family: Wingdings">&uml;</FONT></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt; margin-bottom: 12pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 1in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item
                            2.02</B></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Results
of Operations and Financial Condition.</B></FONT></TD>
</TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On December 13, 2018, Applied DNA Sciences, Inc. (&ldquo;Applied
DNA Sciences&rdquo; or the &ldquo;Company&rdquo;) issued a press release announcing its preliminary results of operations for the
fiscal fourth quarter and year ended September 30, 2018. A copy of the press release is furnished as Exhibit 99.1 to this Current
Report on Form 8-K.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The information furnished pursuant to this Item 2.02, including
Exhibit 99.1, shall not be deemed &ldquo;filed&rdquo; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended
(the &ldquo;Exchange Act&rdquo;), or otherwise subject to the liabilities under that Section and shall not be deemed to be incorporated
by reference into any filing of the Company under the Securities Act of 1933 or the Exchange Act, except as shall be expressly
set forth by specific reference in such filing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 1in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item
                            9.01.</B></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Financial
Statements and Exhibits.</B></FONT></TD>
</TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(<I>d) Exhibits</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left"><A HREF="tv509245_ex99-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</FONT></A></TD><TD STYLE="text-align: justify"><A HREF="tv509245_ex99-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Press
Release of Applied DNA Sciences, Inc. dated December 13, 2018 regarding preliminary results of operations for the fiscal fourth
quarter and year ended September 30, 2018.</FONT></A></TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 39.65pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 39.65pt">Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 39.65pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: December 17, 2018</FONT></TD>
    <TD COLSPAN="2" STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">APPLIED DNA SCIENCES, INC.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="width: 5%; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="width: 45%; padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ James A. Hayward</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">James A. Hayward</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer</FONT></TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXHIBIT INDEX</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 10%; border-bottom: black 1pt solid; padding-right: 2pt; padding-left: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit No.</B></FONT></TD>
    <TD STYLE="width: 2%; padding-right: 2pt; padding-left: 1pt">&nbsp;</TD>
    <TD STYLE="width: 88%; border-bottom: black 1pt solid; padding-right: 2pt; padding-left: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Description</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 2pt; padding-left: 1pt"><A HREF="tv509245_ex99-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</FONT></A></TD>
    <TD STYLE="padding-right: 2pt; padding-left: 1pt">&nbsp;</TD>
    <TD STYLE="padding-right: 2pt; padding-left: 1pt; text-align: justify"><A HREF="tv509245_ex99-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Press Release issued by Applied DNA Sciences, Inc. dated December 13, 2018 regarding preliminary results of operations for the fiscal fourth quarter and year ended September 30, 2018.</FONT></A></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>tv509245_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="margin: 0; text-align: right"><B>&nbsp;</B></P>

<P STYLE="margin: 0; text-align: right"><B><IMG SRC="image_001.jpg" ALT="">&nbsp;</B></P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>Applied
DNA Announces Selected Preliminary Unaudited Fiscal 2018 Year End and Fourth Quarter Financial Results</B></FONT></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>STONY BROOK, N.Y.</B> &ndash; December
13, 2018 &ndash; Applied DNA Sciences, Inc. (NASDAQ: APDN) (&ldquo;Applied DNA&rdquo; or the &quot;Company&quot;), a leader in
large-scale PCR-based DNA manufacturing, announced selected preliminary unaudited financial results for the full fiscal year and
quarter ended September 30, 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; color: #0A0A0A"><B>Preliminary (Unaudited)
Fiscal 2018 Financial Results:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; color: #0A0A0A">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Revenues for fiscal 2018 totaled $3.9 million, a decrease of 18% from
$4.8 million from the same period in the prior fiscal year.&nbsp;The decrease in revenues was attributable to a decrease in revenues
of approximately $2.2 million in the textile industry for protecting cotton and synthetic supply chains. This decrease was offset
by an increase in revenue from Contract Manufacturing of DNA for diagnostics as well as an increase from development projects,
primarily those associated with partners&rsquo; pre-commercial business initiatives in legal cannabis and pharmaceuticals. </FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Deferred revenue increased to $1.9 million as of September 30, 2018
as compared to $352 thousand at September 30, 2017.&nbsp; The reason for this increase is due to the initial cotton order of $1.2
million shipped during June 2018 having extended payment terms and to be recognized to revenue as the payments become due. The
extended payment terms for this shipment are three equal installments due 90, 180 and 270 days from shipment. One-third of the
revenue was recognized during the fiscal fourth quarter of 2018. The increase in deferred revenue is also attributable to fees
received for a variety of contracts that include specific milestones and therefore were not able to be fully recognized as revenue
during the quarter ended September 30, 2018.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Operating expenses for the fiscal year ended September 30, 2018 decreased
by $2.2 million or 13% as compared to the prior fiscal year. The decrease is primarily attributable to a decrease in stock-based
compensation of approximately $1.9 million and bad debt expense of $403 thousand. </FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Net loss for the fiscal year ended September 30, 2018 decreased to
$11.7 million or $0.40 per share, compared with a net loss of $12.9 million or $0.49 per share for the fiscal year ended September
30, 2017.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; color: #0A0A0A"><B>Preliminary (Unaudited)
Fiscal Fourth Quarter Results:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; color: #0A0A0A">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Revenues increased 4% for the fourth quarter of fiscal 2018 to $1.2
million, compared to $1.1 million reported in the fourth quarter of fiscal 2017, and increased 18% as compared to revenues for
the fiscal third quarter ended June 30, 2018 of $1.0 million. The year-over-year increase in revenues is primarily attributable
to an increase in revenues from development and pre-commercial pilots in pharmaceuticals and cannabis. This increase was offset
by a decrease in textile revenues.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Total operating expenses were $4.4 million, compared with $3.7 million
in the prior year&rsquo;s quarter, an increase of approximately 19%. The increase in year-over-year total operating expenses is
attributable to an increase in stock-based compensation expense due to the timing of the annual employee grant, payroll and research
and development expenses, offset by a decrease in depreciation and amortization expense. </FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Net loss for the quarter ended September 30, 2018 was $3.5 million,
or $0.12 per share, compared with a net loss of $2.9 million, or $0.10 per share for the same period in the prior fiscal year and
a net loss of $2.9 million, or $0.10 per share for the third fiscal quarter ended June 30, 2018.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; color: #0A0A0A"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; color: #0A0A0A">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; color: #0A0A0A">The Company also announced
that it anticipates filing its Annual Report on Form 10-K for the fiscal year ended September 30, 2018 with the Securities and
Exchange Commission during the week of December 17, 2018, and will hold an investor call during the week of December 24, 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; color: #0A0A0A">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&ldquo;Our performance in fiscal 2018
reflects execution on pre-commercial sales and business development initiatives to sow new revenue streams by leveraging our proven
DNA taggant technology platform and capitalizing on secular industry trends emphasizing supply chain security, sustainability and
traceability all along the value chain,&rdquo; stated Dr. James A. Hayward, president and CEO of Applied DNA. &ldquo;During the
year we continued to expand our business beyond cotton with diverse partners using synthetic fibers and generating initial revenues
from the legal cannabis and pharmaceutical markets while progressing other programs, such as leather traceability, towards commercialization
while also implementing feasibility pilots with a diverse customer base.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&ldquo;Notable advancements made during
the year included: in textiles, we furthered adoption of our platform for the tagging of non-cotton synthetic textiles to complement
our cotton business that itself has begun to expand internationally; in the nascent legal cannabis industry where compliance with
governmental permitting requirements is fundamental to its future, our partnership with TheraCann has yielded a seed-to-sale tracking
program powered by blockchain and molecular tagging technologies and the development of a tagging system specifically designed
to meet the needs of commercial growers; in pharmaceuticals, we advanced the manufacturing scale-up of our on-dose solution for
enhanced patient safety and supply chain security with partner Colorcon; in biotherapeutics, we formally launched our LineaRx subsidiary
that has already expanded our opportunity-set to include the potentially high-reward therapeutics space. We also saw continued
demand for development pilots that serve as an indicator of growing industry interest in our technology platform and its value
proposition.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Concluded Dr. Hayward, &ldquo;Building
on these advancements, we anticipate revenue from our key business verticals in fiscal 2019 with opportunities for increased contributions
from certain verticals, such as in textiles where we are progressing towards big-box and online retailer adoption of DNA-tagged
synthetic fiber products manufactured by ecosystem partners. In pharmaceuticals, we are pursuing regulatory approval of our molecular
tag that if realized during 2019 should generate a second revenue milestone from Colorcon and make our solution compelling for
pharmaceutical manufacturers in an era of government-mandated serialization practices.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; color: #0A0A0A"><B>Preliminary Results</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; color: #0A0A0A">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; color: #0A0A0A">The financial data contained in this press release are unaudited, preliminary, based upon Applied DNA&rsquo;s good faith estimates
and subject to completion of Applied DNA&rsquo;s financial closing procedures. While Applied DNA expects that its final financial
results for the fiscal year and quarter ended September 30, 2018, following the completion of its financial closing procedures,
will generally be consistent with the amounts provided in this press release, Applied DNA&rsquo;s actual results may differ materially
from these estimates as a result of the completion of its financial closing procedures, as well as final adjustments and other
developments that may arise between now and the time that its financial results for the fiscal year and quarter ended September
30, 2018 are finalized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; color: #0A0A0A">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; color: #0A0A0A">The results provided
in this press release are preliminary and subject to completion and audit of Applied DNA&rsquo;s financial statements in conjunction
with the Company&rsquo;s 2018 Form 10-K filing with the Securities and Exchange Commission anticipated to occur during the week
of December 17, 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; color: #0A0A0A">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About Applied DNA Sciences</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Applied DNA is a provider of molecular technologies that enable
supply chain security, anti-counterfeiting and anti-theft technology, product genotyping and DNA mass production for diagn<FONT STYLE="color: Black">ostics,
personalized medicine and therapeutics.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">Applied DNA makes life real and
safe by providing innovative, molecular-based technology solutions and services that can help protect products, brands, entire
supply chains, and intellectual property of companies, governments and consumers from theft, counterfeiting, fraud and diversion.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">Visit&nbsp;<U>adnas.com</U>&nbsp;for
more information. Follow us on&nbsp;<U>Twitter</U>&nbsp;and&nbsp;<U>LinkedIn</U>. Join our&nbsp;<U>mailing list.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black"><B>Forward Looking Statements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">The statements made by Applied DNA
in this press release may be &quot;forward-looking&quot; in nature within the meaning of the Private Securities Litigation Act
of 1995. Forward-looking statements describe Applied DNA's future plans, projections, strategies and expectations, and are based
on assumptions and involve a number of risks and uncertainties, many of which ar</FONT>e beyond the control of Applied DNA. Actual
results could differ materially from those projected due to the preliminary nature of the financial results set forth herein which
are subject to completion, final adjustment and audit, our history of net losses, limited financial resources, limited market
acceptance, the uncertainties inherent in research and development, future clinical data and analysis, including whether any of
Applied DNA&rsquo;s product candidates will advance further in preclinical research or clinical trial process, including receiving
clearance from the U.S. Food and Drug Administration or equivalent foreign regulatory agencies to conduct clinical trials and
whether and when, if at all, they will receive final approval from the U.S. FDA or equivalent foreign regulatory agencies, <FONT STYLE="color: #0A0A0A; background-color: white">shifting
enforcement priorities of US federal laws relating to cannabis</FONT>, and various other factors detailed from time to time in
Applied DNA's SEC reports and filings, including our Annual Report on Form 10-K filed on December 28, 2017, our subsequent quarterly
reports on Form 10-Q filed on February 8, 2018, May 3, 2018 and August 13, 2018, and our Annual Report on Form 10-K expected to
be filed during the week of December 17, 2018 which are available at&nbsp;www.sec.gov. Applied DNA undertakes no obligation to
update publicly any forward-looking statements to reflect new information, events or circumstances after the date hereof to reflect
the occurrence of unanticipated&nbsp;events, unless otherwise required by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #0070C0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black"><B>Investor contact: </B>Sanjay
M. Hurry, 212-838-3777, LHA Investor Relations, <B>shurry@lhai.com</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black"><B>Web:</B> www.adnas.com</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black"><B>Twitter: </B>@APDN</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black"></FONT></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  H 0$# 2(  A$! Q$!_\0
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+A1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
